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Abstract
Fondaparinux is an antithrombin-dependent factor Xa inhibitor that is used for
thromboprophylaxis of patients undergoing hip fracture surgery, hip or knee replacement, or
abdominal surgery. It is cleared by the kidney and should be used with caution in patients with
renal impairment and avoided in patients with severe renal insufficiency. Recently, several studies
have demonstrated that a lower dose of fondaparinux in patients with moderate renal impairment
appears to be safe and effective. The purpose of this study was to obtain pharmacokinetic and
clinical data on the use of prophylactic fondaparinux inpatients with renal insufficiency
undergoing major abdominal surgery for cancer (n=8) or orthopedic surgery (n=1). Anti-factor Xa
levels were obtained, and a published population pharmacokinetic model for fondaparinux was fit
to the data. The data were analyzed using NONMEM software. Fondaparinux did not appear to
accumulate in these patients, even when the drug was administered for up to twelve days.
Pharmacokinetic analysis revealed thatthe apparent clearance in this population, who were
primarily undergoing cancer surgery, was similar to prior studies in orthopedic surgery patients. In
contrast, lower estimates were obtained for volume of distribution and absorption rate constant
parameters.None of the patients sustained a hemorrhagic complication attributable to
fondaparinux. One patient developed hypoxia in the setting of transient atrial fibrillation and
clinical suspicion for pulmonary embolism, but this was not confirmed radiographically. These
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results support the use of 1.5 mg of fondaparinux every 24 hours for thromboprophylaxis in
patients with renal insufficiency undergoing high-risk surgical procedures.
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Fondaparinux is a synthetic, antithrombin-dependent, factor Xa-specific inhibitor that is
approved in the U.S. for the prevention of deep vein thrombosis in patients undergoing hip
fracture surgery, hip or knee replacement surgery, or abdominal surgery. Numerous studies
have demonstrated this drug's safety and efficacy in these clinical settings [1-3], and the
2012 Guidelines from the American College of Chest Physicians includes fondaparinux as a
thromboprophylactic alternative for patients undergoing orthopedic [4] as well as for general
and abdomino-pelvic surgical procedures [5].
Fondaparinux is mainly excreted by the kidneys, with a terminal plasma half-life of 17 to 21
hours, depending on patient age [6]. Following total hip arthroplasty, anti-factor Xa levels
were shown to gradually increase from median values of 0.0 to 0.24 mg/L over a two-week
period during which patients were treated with 2.5 mg/day of fondaparinux, and this
accumulation was more likely in patients with impaired renal function [7]. Consequently, it
is generally recommended that fondaparinux be used with caution in patients with renal
impairment and avoided altogether in patients with severe renal insufficiency (creatinine
clearance < 30 mL/min).
Several studies have explored the use of a lower dose of fondaparinux (1.5 mg daily) in
orthopedic patients with moderate renal impairment (20 to 50 mL/min) [8, 9]. In the
PROPICE trial, a real-world, prospective, multi-center, cohort study, 442 patients with renal
impairment undergoing total hip or knee replacement, or hip fracture surgery, received 1.5
mg/day of fondaparinux for 16 ± 12.5 days [9]. Major bleeding events occurred in 20
patients (4.5%), and clinically relevant bleeding occurred in 2 patients (0.5%). Three
symptomatic distal venous thrombotic events occurred (0.5%), two while on therapy and
one after fondaparinux had been stopped. More recently, the FONDAIR study investigated
the safety and efficacy of fondaparinux at a dose of 1.5 mg daily in 206 acutely ill medical
patients with renal impairment (creatinine clearance of 20 to 50 mL/min) [10]. One patient
sustained a major bleeding event (0.49%), eight had clinically-relevant non-major bleeding
(3.88%), and three developed symptomatic venous thromboembolism (1.46%) [10].
Relatively limited data are available that provide anti-factor Xa data in patients with renal
insufficiency treated with fondaparinux. Recently, Delavenne and colleagues reported
pharmacokinetic data from the PROPICE study, which investigated patients with renal
impairment undergoing major orthopedic surgery [11]. They demonstrated that
fondaparinux exposure was lower in patients with renal impairment treated with 1.5 mg
daily compared to patients with normal renal function treated with 2.5 mg daily (p<0.01)
[11]. We extended these data by investigating a small cohort of patients with renal
insufficiency undergoing major abdomino-pelvic or orthopedic surgery.
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This was a prospective, open-label, single-center, pharmacokinetic (PK) study
(ClinicalTrials.gov identifier NCT01121770). The protocol was approved by the Duke
University Medical Center Institutional Review Board, and informed consent was obtained
from all patients prior to participation in the study.
Patients
The inclusion criteria for this study were: (1) inpatients ≥18 years of age with an estimated
creatinine clearance between 20 to 50 mL/min; (2) anticipated hospitalization including
either abdominal surgery or an elective orthopedic procedure; (3) need for prophylactic
anticoagulant therapy during the hospitalization; and (4) ability to give informed consent.
The estimated creatinine clearance was calculated using the Cockcroft-Gault equation [12,
13]. Exclusion criteria included: (1) anticipated use of aspirin, clopidogrel, or non-steroidal
inflammatory agents during the time when participating in the study; (2) weight less than 50
kg; (3) clinical indication for therapeutic anticoagulation; (4) currently pregnant or breast-
feeding; (5) reported hypersensitivity to fondaparinux; (6) history of thrombocytopenia with
a positive in vitro test for anti-platelet antibodies in the presence of fondaparinux; (7)
bacterial endocarditis; or (8) brain malignancy. Patients were also excluded if there were any
concerns expressed by the primary team that the patient might be at an increased risk for
hemorrhage. Eligibility assessments were made in the outpatient orthopedic and general
surgery clinics prior to admission for surgery. This visit included the creatinine
measurement for calculation of the creatinine clearance.
Study Drug
Fondaparinux was provided by the manufacturer in individual vials (1.5 mg in 0.3 mL).
Study drug was stored in the Duke Investigational Pharmacy Service and dispensed for
individual patient use when needed.
Protocol
Prophylactic anticoagulation was initiated in the post-operative setting when the bleeding
risk was assessed as being minimal by the surgical and anesthesiology services, as per
standard clinical practice. Fondaparinux was administered at a dose of 1.5 mg
subcutaneously every 24 hours, or at an adjusted dosing interval determined from the anti-
factor Xa level, for the duration of the patient's hospital stay. Study drug was discontinued
for major bleeding events and thrombotic events. Continuation of the study drug for minor
bleeding events was determined by the primary physician for the patient and the principal
investigator. At the time of discharge from the hospital, continued thromboprophylactic
therapy in the outpatient setting was permitted at the discretion of the patient's primary
provider.
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The primary objective of the study was to characterize fondaparinux pharmacokinetics (PK)
in patients with severe renal dysfunction. Blood PK samples were collected at the following
time points following the third consecutive dose: 2 to 6 hours after the dose; approximately
12 ± 4 hours after the dose; and 1 to 4 hours prior to the next scheduled dose. PK samples
were subsequently collected daily for as long as the patient was in the hospital.
The secondary objective was to investigate the safety and efficacy of fondaparinux by
monitoring for major and minor hemorrhagic events and thrombotic complications by daily
assessment during study participation. Major bleeding events were defined as any bleeding
associated with severe hemodynamic instability that required transfusion support; bleeding
in a critical site (e.g., retroperitoneal, intracranial); bleeding resulting in a 2 gm/dL drop in
hemoglobin or higher; or bleeding resulting in death. Minor bleeding included any bleeding
or increased bruising not considered major. Thrombotic events included new arterial or
venous thrombosis of any extremity, stroke, myocardial infarction, or pulmonary embolism.
Anti-factor Xa activity was determined by an amidolytic assay using the HemosIL™
Heparin kit (Instrumentation Laboratories, Co., Bedford MA) on an ACL TOP coagulation
analyzer. Concentration curves were constructed using a pool of platelet-poor plasma
(Precision BioLogic, Dartmouth, Nova Scotia, Canada) spiked with increasing
concentrations of fondaparinux. Anti-factor Xa activity was linearly correlated to the
logarithm of the absorbance over the therapeutic range of the agent. Using this assay, the
lower end for reproducible detection of the drug was 0.1 mcg/mL, and the therapeutic range
for fondaparinux was between 0.20 to 0.70 mcg/mL (10% CV for results in the Coagulation
Laboratory).
Additional assays performed at baseline included a serum pregnancy test, platelet count,
prothrombin time (PT), and an activated partial thromboplastin time (aPTT). Tests
performed weekly included a hemoglobin, platelet count, and serum creatinine.
Statistical and PK Analyses
Descriptive statistical analyses of the patient cohort were performed with Microsoft Excel
(Redmond, WA). Figures were generated using the lattice package in the software R
(version 2.15.2) [14]. A population PK analysis utilizing sparse pharmacokinetic data
collected in the study subjects was performed in the software NONlinear Mixed Effects
Modeling (NONMEM, Version 7.2, Icon Development Solutions, Ellicott City, Maryland).
A published population pharmacokinetic model for fondaparinux was fit to the data utilizing
reported final parameter estimates as initial values in this analysis [11]. The structural
component was a two-compartment body model with first order absorption. In the published
model, creatinine clearance (CrCl) was found to be significantly related to the apparent
clearance (CL/F) and scaled using the CrClas described below. In this allometric function,
CL/Fi represents the individual estimate for CL/F for the ith subject; CL/Fstd represents the
typical population clearance estimate in a subject with the median CrCl in the sample; CrCli
is the creatinine clearance value for the ith subject, which is divided by median creatinine
clearance for the population; and θCL is an empirical allometric exponent. Inter-individual
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variability, which was estimated for the first order absorption rate constant (KA) and CL/F,
was described using an exponential function where ηi is a rando n with mean zero and
variance ω2.
In these analyses a combined proportional and additive error model was used to describe the
intra-individual variability. Population parameter estimates and empirical Bayes estimates
(EBE) (i.e., individual PK parameters) for this sample, after applying the published model,
are reported. For values less than 0.1 mcg/mL, half the limit of quantification (i.e., 0.05
mcg/mL) was used [15].
Results
Patients
Nine patients with renal insufficiency were enrolled into the study between September 2010
and February 2012. Baseline characteristics of the study participants are summarized in
Table 1. All of the patients underwent surgical procedures for a urologic malignancy (six
with bladder cancer, two with renal cancer) except for one participant, who underwent a
total knee arthroplasty. The average hospital length-of-stay for the study participants was 8.2
days (range, 5 to 13 days), and, with one exception, all participants underwent their surgical
procedure on the day of admission to the hospital (one patient underwent surgery on Day 2).
Estimated blood loss during surgery for the orthopedic patient was 300 cc, and for the
urologic patients ranged from 300 to 3300 cc (mean, 1419 cc). Two of the urologic patients
also underwent a splenectomy in addition to the planned procedure, one due to a splenic
laceration sustained during dissection of dense splenic adhesions of a large renal mass and
one due to tumor invasion of the spleen.
Drug Administration
Fondaparinux dosing was initiated within 24 hours of the surgical procedure in 5 patients.
Initiation of fondaparinux was delayed in 4 patients for 3 to 7 days, related to hemorrhagic
concerns after the surgical procedure. Thromboprophylaxis continued for an average of 5
days (range, 2 to 12 days). Sequential doses were administered within 24 hours of the prior
dose except for one dose that was delayed for ∼10 hours, due to clerical error in timing.
Patient #8 was converted from thromboprophylaxis with fondaparinux to therapeutic
anticoagulation with enoxaparin after only two days of prophylactic therapy when a clinical
diagnosis of pulmonary embolism was made (described further below). Two patients
discontinued fondaparinux the day before discharge; all other patients continued
fondaparinux until the day of discharge.
Anti-factor Xa Levels
All patients had two or more anti-factor Xa levels checked (mean, 6.7 measurements per
patient; range, 2 to 17 measurements), for a total of 59 anti-factor Xa measurements. Most
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of the measured trough levels (obtained 1 to 4 hours before a scheduled dose) were
minimally elevated or below the lower cut-off limit of the assay (Table 2). Peak levels
(obtained 2 to 6 hours after a dose) ranged from 0.1 to 0.45 mcg/mL (Table 2). The highest
anti-factor Xa level obtained was 0.64 mcg/mL for Patient #5, who had a baseline creatinine
clearance of 33.6 mg/mL, obtained ∼12 hours after the third dose. Three patients received
fondaparinux for five or more days, but there was no evidence for significant drug
accumulation, with a mean peak level of 0.22 mcg/mL (range, 0.1-0.36 mcg/mL; n=5) and
two trough levels of 0.1 mcg/mL, all obtained after day four of treatment with fondaparinux.
Statistical/PK Analysis
Observed versus individual model predictions for all collected data is shown in Figure 1. In
the current sample, population estimates for CLstd/F and Q/F were 0.24 L/h and 0.55 L/h,
respectively; whereas, VC and VP were estimated as 3.79 and 5.13 L, respectively. The
population estimate for the allometric exponent, θCL, was 1.04. Inter-individual variability
could be estimated for KA (31%) and CL/F (104%). Intra-individual variability estimated
using a combined proportional and additive relationship was 34% and 0.03 mcg/mL,
respectively. For individual subjects, the median and range for structural model parameters
where inter-individual variability was incorporated are estimated as 0.34 h-1 (0.26-0.41, KA)
and 0.38 L/h (0.03-0.71, CL/F). The relationship between creatinine clearance and the
individual estimate for CL/F is depicted in Figure 2.
Clinical Events
One patient developed hypoxia in the early postoperative setting, within 24 hours of the first
dose of fondaparinux. This patient had a prior history of deep vein thrombosis and had an
inferior vena cava filter placed prior to surgery. He also had a transient run of asymptomatic
atrial fibrillation early in his postoperative course and subsequently developed increased
oxygen requirements. A CT angiogram was not performed due to renal insufficiency
(creatinine of 2.2), and a ventilation-perfusion scan was not performed because of an
abnormal chest X-ray. An ultrasound revealed two small echogenic eccentric foci within the
right internal jugular vein, consistent with non-occlusive thrombus vs. sequelae of prior
thrombus. No other evidence of thrombus was identified in the patient, but he was converted
to therapeutic anticoagulation given his history and the clinical concern for possible
pulmonary embolism.
None of the patients developed clinically overt hemorrhagic complications. A single patient
experienced a drop in the hemoglobin level by more than 2 gm/dL while receiving
prophylactic fondaparinux, and this patient also received one unit of packed red blood cells
on Hospital Day 4. The fondaparinux level in this patient at the time when the hemoglobin
dropped was <0.1 mcg/mL, and it was not discontinued until later in the hospital course. A
similar drop in the hemoglobin level occurred in two additional patients, but in both of these
individuals, the drop occurred after the surgery but prior to initiating the fondaparinux.
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Renal insufficiency is a common condition found in patients undergoing surgical
procedures, especially in the older patient population. Patients with chronic kidney disease
undergoing orthopedic surgery are at an increased risk for postoperative morbidity [16],
including thrombotic complications [17]. Similarly, patients with renal insufficiency are at
an increased risk for cardiovascular events following urologic cancer surgery [18].
Consistent with these reports, one of the patients reported in this study developed worsening
hypoxia in the early postoperative setting that was concerning for a possible venous
thromboembolic event.
We investigated the use of fondaparinux as a thromboprophylactic agent in patients with
moderate renal insufficiency undergoing abdominopelvic surgery for treatment of cancer or
orthopedic surgery. Several studies have suggested that a reduced dose of fondaparinux, 1.5
mg/day subcutaneously, is effective and safe in patients with renal insufficiency. This dose
has been looked at in patients with renal insufficiency undergoing orthopedic surgery [9] but
it has not been previously described in patients undergoing cancer surgery.
Peak anti-factor Xa levels ranged from below the lower limit of detection to 0.45 mcg/mL
(Table 2). These data complement existing datasets by providing a range of anti-factor Xa
levels that can be expected at the time points studied in patients with renal insufficiency, if
there is a clinical indication to check the level. It is possible that an individual patient who
has higher levels than those observed in this study might have an increased risk for
hemorrhagic complications, but this would need to be confirmed prospectively.
We applied a published population pharmacokinetic model developed in a large sample of
patients with renal impairment undergoing orthopedic surgery [11] to this small sample of
high-risk operative patients. When structural population PK parameter estimates are
compared, the apparent clearance in this and the prior population was similar, whereas lower
estimates were obtained for volume of distribution and absorption rate constant parameters.
Greater imprecision in parameter estimates was observed, likely due in part to a small
sample size and sparse sampling. Inter-individual variability estimate for KA was lower
(31% vs. 90%), whereas variability in CL/F was higher (104% vs. 33%) in the current
sample. Although the range of CrCl values observed in this sample was narrower, the
majority of the patients had a urologic malignancy, which may have contributed to the
greater inter-individual variability in CL/F.
We did not observe increased bleeding with fondaparinux at 1.5 mg/day in the patients
treated in this small study. Although one patient did receive a transfusion because of a
dropping hematocrit, none of the patients developed a clinically overt hemorrhagic event. In
addition, the anti-factor Xa levels obtained immediately prior to a subsequent dose were
either below the lower limit of detection, or only minimally elevated (Table 2).
One patient developed worsening hypoxia that was concerning for pulmonary embolism,
although this could not be directly proven. The risk for postoperative venous
thromboembolism is particularly high in patients undergoing abdominal or pelvic surgery
for cancer [5], and this patient also had a prior history of deep vein thrombosis. Since he had
Hester et al. Page 7






















been on warfarin prior to the surgery, he was simply restarted on therapeutic
anticoagulation. It is notable that there are no large phase III randomized trials of
thromboembolism prophylaxis in urological patients (most studies combine this patient
population with patients undergoing various abdominal and pelvic procedures)[5]. This
patient population has a high rate of renal insufficiency, however, making drug dosing
difficult.
One limitation of our study is the small number of study participants, primarily due to
difficulties encountered in enrolling a sufficient number of patients who stayed in the
hospital for an appropriate length of time for the study. Orthopedic surgery patients were
frequently discharged within a few days of surgery, even those with renal insufficiency. Our
study was not designed to be conducted in the outpatient setting, restricting our population
of eligible patients to individuals who were expected to be in the hospital for at least three or
four days following surgery. It is possible that fondaparinux at this dose could be used in the
outpatient setting for postoperative thromboprophylaxis in patients with renal insufficiency,
but our study did not address this approach to therapy.
In conclusion, we demonstrated that 1.5 mg fondaparinux administered subcutaneously
every 24 hours in high-risk surgical patients with renal impairment was associated with
trough anti-factor Xa levels ranging from < 0.1 mcg/mL to 0.22 mcg/mL, even after as many
as12 doses of study drug (Table 2). We theorize that this dose of fondaparinux is likely to be
safe given the resulting plasma concentrations of drug are comparable to those seen in
patients with better renal function. These patients are clinically complex and at risk for
hemorrhagic as well as thrombotic events. Determining safe strategies for
thromboprophylaxis is essential in this post-operative population of patients with renal
insufficiency.
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Observed versus individual model predicted fondaparinux concentrations.Anti-factor Xa
levels vs. time are shown for all collected data points.For values less than 0.1 mcg/mL, half
the limit of quantification (i.e., 0.05 mcg/mL) is plotted.
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Relationship between creatinine clearance and the individual estimate for apparent clearance
(CL/F).
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Table 1
Demographics of study patients.
Characteristic Participants
Age (years) 76 (52 to 86)*
Male 6
Race 7 Caucasian, 2 African-American
Weight, mean (kg) 69 (53 to 97)
Creatinine at enrollment (mg/dL) 1.3 (1.1 to 1.7)
Calculated creatinine clearance at enrollment (mL/min)† 44.4 (29.5 to 54.6)
Maximal postoperative creatinine (mg/dL) 1.5 (1.0 to 4.5)
*
Data are median (range) except where ranges are not indicated.
†
Calculated by Cockcroft-Gault formula.
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Table 2
Anti-factor Xa levels
Timepoints* Measurements (N) Median Anti-factor Xa level, mcg/mL Range, mcg/mL
2-6 hrs after dosing (peak) 10 0.25 <0.1-0.45
12 ± 4 hrs after dosing (mid-point) 16 0.16 0.1-0.64
1-4 hrs before subsequent dose (trough) 7 0.10 <0.1-0.22
*
Twenty-four anti-factor Xa results fell outside these timepoint ranges.
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